FDA Notifies Public About Recall Of CBD Product That Tested High For Lead
The Food and Drug Administration (FDA) is publicizing a voluntary recall of a CBD product, notifying consumers about potentially high levels of lead in a batch of tinctures that were tested by the Florida Department of Agriculture and Consumer Services.
The federal agency reported on Friday that Summitt Labs, which produces a wide range of hemp-derived cannabidiol products, voluntarily pulled a batch of its Kore Organic watermelon tincture after the state agriculture department conducted a test on a random sample and found high levels of lead, which when ingested can cause various symptoms such as pain, nausea and kidney damage.
=======================================================================================
Canadian study finds that enzymes in cannabis could treat COVID-19
The study, published in peer journal Preprints, was conducted by the scientists in April, and the results were released in a non-peer-reviewed, preclinical study titled “In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues” earlier this month, according to a release from pharmaceutical research company Pathway RX.
The Food and Drug Administration (FDA) is publicizing a voluntary recall of a CBD product, notifying consumers about potentially high levels of lead in a batch of tinctures that were tested by the Florida Department of Agriculture and Consumer Services.
The federal agency reported on Friday that Summitt Labs, which produces a wide range of hemp-derived cannabidiol products, voluntarily pulled a batch of its Kore Organic watermelon tincture after the state agriculture department conducted a test on a random sample and found high levels of lead, which when ingested can cause various symptoms such as pain, nausea and kidney damage.
=======================================================================================
Canadian study finds that enzymes in cannabis could treat COVID-19
The study, published in peer journal Preprints, was conducted by the scientists in April, and the results were released in a non-peer-reviewed, preclinical study titled “In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues” earlier this month, according to a release from pharmaceutical research company Pathway RX.
Last edited: